Margaret Porter Scott - VP Biochemical Cellular Pharmacology, Biochemical & Cellular Pharmacology, Drug Discovery

Margaret Porter Scott

VP Biochemical Cellular Pharmacology, Biochemical & Cellular Pharmacology, Drug Discovery

"Discovering and developing the next generation of therapeutics will not be easy – and that’s what motivates me."
10
Years at Genentech
8
Publications at Genentech
3
Awards & Honors

I joined Genentech because great science with great people is what I want do. I have spent my career seeking the best ways to “reduce to practice” the key aspects of highly complex disease biology so that new drug discovery programs can be initiated and progressed. This leads to a tight partnership with Disease Biology and I count myself so fortunate to have a role in Biochemical and Cellular Pharmacology focusing on the portfolio of cancer targets in partnership with the world-class Oncology Biology team here at Genentech.

SUMMARY OF PUBLICATIONS (PDF)

Featured Publication

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Proc Nat. Acad Sci. 2010 107(49):20980-5.

Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA.